评估治疗响应值,以实现代谢相关脂肪性肝病的成本有效治疗
Eileen L Yoon1,2, Jeong-Yeon Cho3, Huiyul Park4
1Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, Republic of Korea.
Clinical and molecular hepatology
|November 3, 2025
概括
新的代谢功能障碍相关脂肪性肝病 (MASLD) 药物需要持续的耐用性和初始反应才能具有成本效益. 这些因素,以及患者纤维化阶段,是治疗疗效的关键.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药物经济学 药物经济学
- 临床试验建模临床试验建模
背景情况:
- 第一个批准的代谢功能障碍相关的脂肪性肝病 (MASLD) 药物显示出有限的疗效.
- 需要评估新型MASLD治疗方法的成本效益.
研究的目的:
- 确定影响假设MASLD药物的成本效益的关键因素.
- 评估一种新的MASLD药物的治疗疗效.
主要方法:
- 马尔科夫模型模拟了MASLD的自然史,包括纤维化进展,心血管疾病 (CVD) 风险和死亡率.
- 该模型评估了一个假设的药物 (药物X,每年20,000美元) 假设纤维化回归的好处.
- 敏感性分析探讨了对增量成本效益比率 (ICER) 有影响的因素.
主要成果:
- 药物X产生了68,010美元/QALY的ICER,表明成本效益低于10万美元/QALY的门.
- 这种药物在20年内提供了1.32 QALY和1.20 LY的增量增长.
- 成本效益要求至少有15%的初始回归差距和3%的持续耐久性差距.
结论:
- 持续的药物耐用性对于MASLD治疗的长期成本效益至关重要.
- 患者基线纤维化阶段分布显著影响治疗结果.
- 初始治疗响应率是新的MASLD药物的经济可行性的关键决定因素.
相关概念视频
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
176
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
176
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
526
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
526
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
209
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
209
01:29Chronic Pancreatitis II: Collaborative Care
306
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
306